ProCE Banner Activity

PARP Inhibition in the Treatment of Pancreatic Cancer: Current and Future Perspectives on Personalized Therapy

Slideset Download
Download this slideset on the current advances and evolving landscape of PARP inhibitors for patients with pancreatic cancer.

Released: December 14, 2021

Expiration: December 13, 2022

No longer available for credit.

Share

Faculty

Dirk Arnold

Dirk Arnold, MD, PhD

Director
Asklepios Tumorzentrum Hamburg
Department of Oncology
AK Altona
Hamburg, Germany

Michel Ducreux

Michel Ducreux, MD, PhD

Full Professor of Cancerology
Faculty of Medicine
University of Paris-Saclay
Department of Medicine
Gustave Roussy
Villejuif, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Dirk Arnold, MD, PhD

Director
Asklepios Tumorzentrum Hamburg
Department of Oncology
AK Altona
Hamburg, Germany

Dirk Arnold, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Lilly, MSD, Pierre Fabre, and Roche; funds for research support from AstraZeneca, Bristol-Myers Squibb, and Pierre Fabre; fees for non-CME/CE services from Amgen, AstraZeneca, Bristol-Myers Squibb, MSD, Pierre Fabre, and Roche; and other financial or material support from AstraZeneca.

Michel Ducreux, MD, PhD

Full Professor of Cancerology
Faculty of Medicine
University of Paris-Saclay
Department of Medicine
Gustave Roussy
Villejuif, France

Michel Ducreux, MD, PhD, has disclosed that he has received consulting fees from Amgen, Bayer, HalioDX, Ipsen, Keocyt, Lilly, Merck Serono, MSD, Roche, and Servier.